News · FDA and regulation

The 503B bulks comment period closed on 30 July. FDA is reviewing

The window on Docket No. FDA-2018-N-3240 shut at 11:59 p.m. Eastern on 30 July. Late comments will not be considered. What happens next has no published deadline.

Event date 2026-07-30 · Published 2026-08-01 · Docket No. FDA-2018-N-3240

What closed

FDA published its proposal on 1 May 2026 at 91 FR 23431 (FR Doc 2026-08552, pages 23431–23444), finding no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances. The notice opened a 60-day comment period.

On 26 June FDA extended that period at 91 FR 38719 (FR Doc 2026-12937). The regulations.gov electronic filing system accepted comments until 11:59 p.m. Eastern at the end of 30 July 2026. Written submissions were timely if received on or before that date. The notice states that late, untimely filed comments will not be considered.

Correction: the extension was 30 days, not 60

Our earlier coverage of the extension stated that FDA granted a 60-day extension. That is wrong, and the error is ours.

What the notice records is that FDA received a request for a 60-day extension, and granted 30 days. The agency stated that a 30-day extension, rather than 60, appropriately balances allowing adequate time for interested persons to submit comments against avoiding significant delay of agency action on these issues.

The distinction matters for reading the agency’s posture: it granted less time than was asked for, and said in terms that it did not want to delay. We have logged this in the corrections record and amended the earlier page.

What FDA does next

Under the process FDA describes in the May notice, the agency considers the comments received, then considers whether input from the Pharmacy Compounding Advisory Committee would be helpful and seeks it if so. Section 503B does not require FDA to consult the committee before developing the list.

FDA may then finalise the proposed determination without change, or finalise a modification reflecting new evidence or analysis regarding clinical need. Either way it publishes a final determination in the Federal Register setting out its rationale.

Once that final determination publishes, FDA will no longer consider comments submitted to the docket regarding that substance. Interested parties may then submit a citizen petition under 21 CFR 10.30.

No statutory deadline governs how long the review takes. Earlier substances on this docket have moved on timescales measured in years rather than weeks.

What did not happen on 30 July

Compounded GLP-1s were not banned on 30 July. No rule took effect. No enforcement position changed. The closing of a comment window is a procedural step, and the proposal remains a proposal.

We flag this because the previous procedural milestones on this docket were widely reported as though they were decisions, and we expect the same here. If you see a headline stating that compounded semaglutide is now illegal, check whether it cites a final determination published in the Federal Register. As of this page’s capture date, none exists.

What we are watching

A Federal Register notice making a final determination on the three substances. Whether FDA refers the question to the Pharmacy Compounding Advisory Committee, which met in July on an unrelated set of peptide nominations. And whether any modification appears in a final determination, which would indicate a comment moved the analysis.

Our explainer on what the clinical need test actually asks sets out the standard the determination will be written against.

Frequently asked questions

Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.